Clinical Trial Update: HMG-CoA Reductase add-on in Chronic Kidney Disease Patients With Proteinuria [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update examining HMG-CoA reductase add-on therapy in chronic kidney disease patients with proteinuria.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Proteinuria

Drugs mentioned

• HMG-CoA reductase inhibitor add-on therapy

Snippet

Sponsor: Yuhan Corporation | Conditions: Chronic Kidney Disease, Proteinuria | Phase 4 | Status: UNKNOWN